Sophia Rein on HIV treatment with INSTIs and cardiovascular events The Lancet HIV in conversation with

Peter Hayward is joined by Sophia Rein of the Harvard T H Chan School of Public Health to discuss an emulation of target trials using cohort data to look at risk of cardiovascular events in people taking INSTIs for HIV.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv